Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

J Weber; M Mandala; Vecchio M Del; HJ Gogas; AM Arance; CL Cowey; S Dalle; M Schenker; V Chiarion-Sileni; I Marquez-Rodas; JJ Grob; MO Butler; CheckMate 238 Collaborators

doi:10.1056/nejmoa1709030

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

J Weber, M Mandala, Vecchio M Del, HJ Gogas, AM Arance, CL Cowey, S Dalle, M Schenker, V Chiarion-Sileni, I Marquez-Rodas, JJ Grob, MO Butler, CheckMate 238 Collaborators

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	The New England Journal of Medicine
DOIs	https://doi.org/10.1056/nejmoa1709030
Publication status	Published - Sept 2017

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/nejmoa1709030

Cite this

@article{6e84b0dcd545482782a9b8e0be4eb9a3,

title = "Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.",

author = "J Weber and M Mandala and Del, {Vecchio M} and HJ Gogas and AM Arance and CL Cowey and S Dalle and M Schenker and V Chiarion-Sileni and I Marquez-Rodas and JJ Grob and MO Butler and Collaborators, {CheckMate 238}",

year = "2017",

month = sep,

doi = "10.1056/nejmoa1709030",

language = "English",

journal = "The New England Journal of Medicine",

issn = "1533-4406",

publisher = "Massachussetts Medical Society",

}

TY - JOUR

T1 - Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

AU - Weber, J

AU - Mandala, M

AU - Del, Vecchio M

AU - Gogas, HJ

AU - Arance, AM

AU - Cowey, CL

AU - Dalle, S

AU - Schenker, M

AU - Chiarion-Sileni, V

AU - Marquez-Rodas, I

AU - Grob, JJ

AU - Butler, MO

AU - Collaborators, CheckMate 238

PY - 2017/9

Y1 - 2017/9

UR - http://europepmc.org/abstract/med/28891423

U2 - 10.1056/nejmoa1709030

DO - 10.1056/nejmoa1709030

M3 - Article

C2 - 28891423

SN - 1533-4406

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

ER -

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Cite this